Michael M. Gaba is a Partner in the Washington, D.C., office of Holland & Knight where he is the federal policy leader of the firm’s national Healthcare & Life Sciences Team. His regulatory and legislative life sciences practice includes counseling and representing medical device and biotech companies before the U.S. Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS) and the U.S. Congress.
Mr. Gaba advises clients on a wide range of regulatory issues related to FDA reform and efficiency, with an emphasis on proper implementation of FDAMA, FDAAA, and FDASIA. He also provides pre-market strategic counseling and post-market surveillance and enforcement advice, with a particular focus on combination product approval, labeling and promotion. Helping clients get to market and stay there, Mr. Gaba counsels medical device and biotech companies on coverage, coding and reimbursement strategies before CMS to enhance patient access to innovative technologies.
Mr. Gaba writes extensively and lectures on numerous regulatory issues, including comparative effectiveness, interagency coordination and its impact in the post-market context, defending FDA enforcement actions, as well as coverage, coding and reimbursement strategies for medical device manufacturers.
Prior to joining Holland & Knight, Mr. Gaba worked on Capitol Hill in the personal offices of Congressman Robert Garcia (D-NY) and Senator Bill Bradley (D-NJ), and on the Labor and Human Resources Committee for Senator Edward Kennedy (D-MA).
He received his B.A. from Franklin & Marshall College and his J.D. from the George Washington University Law School.
Mr. Gaba is a co-author of the Bloomberg BNA Health Law & Business Portfolio Series No. 3250, Life Sciences Compliance: A Pre-Market and Post-Market Road Map.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)